RRx-001
- Generic Name
- RRx-001
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C5H6BrN3O5
- CAS Number
- 925206-65-1
- Unique Ingredient Identifier
- 7RPW6SU9SC
- Background
RRx-001 has been used in trials studying the treatment of Lymphomas, Brain Metastases, Cholangiocarcinoma, Colorectal Neoplasms, and Malignant Solid Tumor, among others.
- Associated Conditions
- -
- Associated Therapies
- -
EpicentRx's Oncolytic Virus-delivered TGFβ Inhibitor, AdAPT-001, Receives FDA Fast Track
EpicentRx's AdAPT-001, an oncolytic adenovirus-delivered TGFβ inhibitor, received FDA Fast Track designation for treating recurrent or refractory advanced or metastatic soft tissue sarcoma (STS) in combination with nivolumab or atezolizumab. This designation aims to expedite the development and approval of drugs addressing serious conditions like STS, which has high heterogeneity and poor prognosis. AdAPT-001 is designed to inflame the tumor microenvironment and neutralize TGFβ, potentially offering new treatment options for STS patients.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath